No relevant species; immunodeficient mouse B-ALL xenograft (non-GLP) only
“The absence of GLP compliance is acceptable since standard single or repeat-dose toxicity studies could not be performed due to lack of a relevant animal model.”
Patient-specific human T-cell product cannot be given to immunocompetent animals
“The lack of single-dose toxicity studies is acceptable, since tisagenlecleucel is a patient specific product, which is not appropriate to administer to immune competent animals.”
No surrogate; human CART-19 cells (1:1 mix of LTG118/LTG119 constructs) in xenograft mice
“The exact clinical construct was used in the studies and the vectors were research grade.”
✓ VerifiedFDA pharmacology/toxicology review, p. 15Source ↗
Species: general tox
Human B-ALL tumor-bearing mice only (non-GLP single IV biotoxicity/biodistribution study to Day 217); no standard repeat-dose toxicity
“An in vivo study was conducted to evaluate toxicity and BD in tumor-bearing mice receiving i.v. injection of CTL019 at 1, 5, and 20x106 cells/mouse and observed up to Day 217 post-injection (p.i.) with three terminal sacrifices.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
Species: DART
Not conducted
“No preclinical reproductive studies were conducted with CTL019 to assess whether it can cause fetal harm when administered to a pregnant woman.”
✓ VerifiedFDA pharmacology/toxicology review, p. 3Source ↗
Species: carcinogenicity
Not conducted (no rodent carcinogenicity assessment)
“Classical genotoxicity assays and carcinogenicity assessment in rodent models were not performed for CTL019.”
✓ VerifiedFDA pharmacology/toxicology review, p. 3Source ↗
Surrogate used in
No surrogate used; exact clinical CAR construct (research-grade vector) tested in mice
“The exact clinical construct was used in the studies and the vectors were research grade.”
✓ VerifiedFDA pharmacology/toxicology review, p. 15Source ↗